Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 10029575)

1.

Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Tucci M, Stucci S, Strippoli S, Dammacco F, Silvestris F.

Oncologist. 2011;16(7):1040-8. doi: 10.1634/theoncologist.2010-0327. Epub 2011 Jun 9. Review.

2.

Immune therapies.

Prabhala RH, Munshi NC.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1217-30, x-xi. Review.

3.

Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.

Kovaleva M, Bussmeyer I, Rabe B, Grötzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J.

J Virol. 2006 Sep;80(17):8510-20.

4.

Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma.

Brimnes MK, Svane IM, Johnsen HE.

Clin Exp Immunol. 2006 Apr;144(1):76-84.

5.

Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.

Messmer D, Telusma G, Wasil T, Messmer BT, Allen S, Rai KR, Chiorazzi N.

Mol Med. 2004 Jul-Dec;10(7-12):96-103.

6.

Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.

Ablashi DV, Chatlynne LG, Whitman JE Jr, Cesarman E.

Clin Microbiol Rev. 2002 Jul;15(3):439-64. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk